Q3 2024 Inovio Pharmaceuticals Inc Earnings Call Transcript

Nov 14, 2024 / 09:30 PM GMT

Release Date Price: MXN98 (-8.84%)

Transcript 8-K10-Q

Key Points

Positve

Inovio Pharmaceuticals Inc (INO) reported significant progress in advancing their lead product candidate, INO-3107, towards commercialization.
The company presented compelling immunology data supporting the mechanism of action for INO-3107, indicating its potential to reduce or eliminate surgeries for RRP patients.
Inovio Pharmaceuticals Inc (INO) held a positive pre-BLA meeting with the FDA and is on track to submit their BLA by mid-2025.
The company has reduced operating expenses by 24% year-over-year, demonstrating financial discipline.
Inovio Pharmaceuticals Inc (INO) closed the third quarter with $84.4 million in cash, cash equivalents, and short-term investments, with no debt.

Negative

Inovio Pharmaceuticals Inc (INO) identified a manufacturing issue with the single-use component of their device, which needs resolution before proceeding with certain trials.
The company's cash position decreased from $145.3 million at the end of 2023 to $84.4 million by the end of Q3 2024.
The initiation of the Phase 3 trial for INO-3112 is dependent on resolving the device manufacturing issue.
Inovio Pharmaceuticals Inc (INO) has not yet reached out to regulatory bodies in Japan and China for INO-3107, potentially delaying market entry in these regions.
The company faces potential competition from Precigen's product, which may launch in 2025, impacting market dynamics for INO-3107.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INO.OQ - Inovio Pharmaceuticals Inc
Q3 2024 Inovio Pharmaceuticals Inc Earnings Call
Nov 14, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, ladies and gentlemen and welcome to the Innov third quarter, 2024 Financial assaults conference call at this time. All lines are Neles on the mode following the presentation, we will conduct a question and answer session.

If at any time during this call, you require immediate assistance. Please press star zero for the operator.

This call is being recorded on Thursday, November 14th, 2024.

I would now like to turn the conference over to Thomas hong, Manager of Investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.